5.6. Analysis.

Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ European Quality of Life 5‐dimensions questionnaire

Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ European Quality of Life 5‐dimensions questionnaire